secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001689375-23-000008
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada closes $224M upfront Vertex collaboration for DM1; cash runway to H2 2025
--------------------------------------------------------------------------------

- Closed global collaboration with Vertex for ENTR-701 and other DM1 research; Vertex leads development.
- Received $224M upfront plus $26M equity investment at $16.26 per share (1,618,613 shares).
- Eligible for up to $485M in research, development, regulatory, and commercial milestones.
- Entitled to tiered royalties on future net sales of any products from the collaboration.
- Proceeds extend cash runway into second half of 2025, funding DMD and other EEV programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000008/0001689375-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000008/trda-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer